Somatrem
As of the edition of 20 October 2026, Somatrem is a protein: marketed, first approved in 1985 (US); acts on GHR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1985
- Kind
- Protein
- Brand name
- Protropin
- First approved
- 17 October 1985 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Roche
- Registered trials
- 1, 0 stopped early
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GHR | Growth hormone receptor | P10912 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Applicant and Lead sponsor of trials | 1985 to now |